According to our (Global Info Research) latest study, the global Omalizumab Biologic Injection market size was valued at US$ 66.80 million in 2025 and is forecast to a readjusted size of US$ 129 million by 2032 with a CAGR of 8.5% during review period.
Omalizumab Biologic Injection is a monoclonal antibody drug targeting immunoglobulin E (IgE), mainly used for the treatment of allergic asthma, chronic spontaneous urticaria, nasal polyps, and other IgE-mediated diseases. It works by binding to free IgE in the blood, thereby reducing allergic reactions and inflammation. Upstream of the industry chain mainly includes biotechnology raw materials, cell culture media, recombinant protein expression systems, bioreactor equipment, and contract development and manufacturing organizations (CDMOs). Midstream consists of biopharmaceutical companies producing original biologics and biosimilars, formulation manufacturers, fill-finish providers, and cold chain logistics companies. Downstream includes hospitals, specialty clinics, retail pharmacies, online pharmacies, and patients suffering from severe allergic or autoimmune-related conditions. With the growing prevalence of allergic diseases and the expansion of biologic therapies, the market demand for Omalizumab Injection continues to increase globally.
This report is a detailed and comprehensive analysis for global Omalizumab Biologic Injection market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Omalizumab Biologic Injection market size and forecasts, in consumption value ($ Million), 2021-2032
Global Omalizumab Biologic Injection market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Omalizumab Biologic Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Omalizumab Biologic Injection market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Omalizumab Biologic Injection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Omalizumab Biologic Injection market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech, BiosanaPharma, Mabpharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Omalizumab Biologic Injection market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
150 mg/mL
75 mg/0.5 mL
Market segment by Age
For Adults
For Teenagers
For Children
Market segment by Application
Hospital
Clinic
Others
Market segment by players, this report covers
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Omalizumab Biologic Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Omalizumab Biologic Injection, with revenue, gross margin, and global market share of Omalizumab Biologic Injection from 2021 to 2026.
Chapter 3, the Omalizumab Biologic Injection competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Omalizumab Biologic Injection market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Omalizumab Biologic Injection.
Chapter 13, to describe Omalizumab Biologic Injection research findings and conclusion.
Summary:
Get latest Market Research Reports on Omalizumab Biologic Injection. Industry analysis & Market Report on Omalizumab Biologic Injection is a syndicated market report, published as Global Omalizumab Biologic Injection Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Omalizumab Biologic Injection market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.